for 'Well-Prepared CompTIA CAS-005 Latest Test Braindumps Are Leading Materials - Accurate CAS-005: CompTIA SecurityX Certification Exam š The page for free download of ā· CAS-005 ā on { www.pdfvce.com } will open immediately š„CAS-005 Exam Training'
We have a powerful purpose in going beyond the ordinary to make a meaningful impact in rare patientsā lives. Thatās why we come to work every day. Peter Heerma has served as chief commercial officer at Travere Therapeutics since October 2019. He is responsible for leading the companyās commercial organization including commercialization strategy for approved […]
We have a powerful purpose in going beyond the ordinary to make a meaningful impact in rare patientsā lives. Thatās why we come to work every day. Peter Heerma has served as chief commercial officer at Travere Therapeutics since October 2019. He is responsible for leading the companyās commercial organization including commercialization strategy for approved […]
SAN DIEGO, November 30, 2020 ā SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) — Travere Therapeutics (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 DUPLEX Study. The pivotal DUPLEX Study is evaluating the safety and efficacy of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney condition that often leads to end-stage kidney disease (ESKD). Topline efficacy data from the interim 36-week proteinuria endpoint analysis are expected in the first quarter of 2021. Read the press release >
Wednesday, July 19, 2023 – For his success in Travere Therapeuticsā business growth and commitment to supporting biotech and wellness,Ā San Diego Business JournalĀ named Eric Dube, Ph.D., CEO of the Year in the Medium-Size Company Category. āI feel like I have the greatest job in the world. I work with individuals who are so […]
Data support the Companyās lead investigational product candidate sparsentan SAN DIEGO , Oct. 26, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present data from its sparsentan programs, including long-term clinical
We strive every day to connect our collective talents to find, develop and bring innovative therapies to people living with rare disease. Mr. Logan is chief business officer and a member of the executive team at Travere Therapeutics. He is responsible for leading corporate development, strategic planning, program management and information technology at Travere. Prior […]
SAN DIEGO and ST. GALLEN , Switzerland , Aug. 22, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) and CSL Vifor today announced that the EMA has accepted for review the Conditional Marketing Authorization (CMA) application for sparsentan for the treatment of IgAN, a rare kidney disorder and leading cause of end-stage kidney disease (ESKD).
SAN DIEGO and ST GALLEN, Switzerland, Sept. 15, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) and Vifor Pharma today announced the companies have entered into a joint collaboration and licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand. Sparsentan is a novel investigational product candidate currently being evaluated in pivotal Phase 3 clinical studies for the treatment of FSGS and IgAN, two rare progressive kidney disorders and leading causes of end-stage kidney disease. There are currently no approved medicines indicated for FSGS or IgAN. Sparsentan has been granted Orphan Drug Designation for the treatment of FSGS and IgAN in the U.S. and Europe.
SAN DIEGO,Ā Feb. 18, 2021Ā (GLOBE NEWSWIRE) —Ā Travere Therapeutics, Inc.Ā (NASDAQ: TVTX) today announced theĀ European CommissionĀ (EC) has granted orphan designation to sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD).
SAN DIEGO,Ā Jan. 12, 2021Ā (GLOBE NEWSWIRE) —Ā Travere Therapeutics, Inc.Ā (NASDAQ: TVTX) today announced that theĀ U.S. Food and Drug AdministrationĀ (FDA) has granted Orphan Drug Designation to sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD).